INFOS !
  • NEW ADDRESS: The management team of ERN-EYE is moving! Starting from March 19, you can find us at 1 Rue Eugène Boeckel, 67000 Strasbourg.

Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

Amsterdam University Medical Center / Leiden University Medical Center

In this page

How to contact the center

Full member

HCP Center

AMC / LUMC are modern university medical centers for research, education and patient care with a high quality profile and a strong scientific orientation. Its unique research practice, ranging from pure fundamental medical research to applied clinical research, places AMC / LUMC among the world top. This enables AMC / LUMC to offer patient care and education that is in line with the latest international insights and standards – and helps it to improve medicine and healthcare both internally and externally.

AMC / LUMC act as knowledge centers for topics in the field of public health with an impact on society, it has a directive function in the region, and acts as centers for continuing education and further training for medical professionals.

AMC / LUMC are centers of expertise for rare eye diseases, with active clinical and basic research on this topic. The AMC ophthalmogenetic database is among the largest in the world.

Picture : Steven Lek

Contact

Amsterdam University Medical Center / Leiden University Medical Center

Albinusdreef 2
2333 ZA Leiden
Netherlands

Team

Pr Camiel BOON

Representative

Netherlands

Anterior Segment Rare Eye Diseases (WG4), Genetic Diagnostics (TWG6), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

Dr Axel PETZOLD

Netherlands

Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8)
See more

Dr Lucas Wenninger

Netherlands

Neuro-Ophthalmology Rare Diseases (WG2)
See more

Clinical trials

NCT05537220 - Recruiting, Active

NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa

Interventional
See the trial
voir la fiche

NCT04671433 - Active, Not recruiting

Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Interventional
See the trial
voir la fiche
NCT04794101 - Active, Not recruiting

Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Interventional
See the trial
voir la fiche
NCT03079141 - Unknown

Half-dose photodynamic therapy versus eplerenone treatment in chronic centralserous chorioretinopathy.

Interventional
See the trial
voir la fiche
NCT04926129 - Completed

Natural history of the progression of X-linked retinitis pigmentosa.

Observational
See the trial
voir la fiche
NCT06114537 - Completed

Prospective Clinical Trial to Evaluate the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in Retinoschisis: The AXIS Trial

Interventional
See the trial
voir la fiche

A multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of oral soraprazan in Stargardt disease

Interventional
See the trial
voir la fiche
NCT03349801 - Active, Not recruiting

Development of Novel Clinical Endpoints for Interventional Clinical Trials With a Regulatory and Patient Access Intention in Patients With Intermediate Age-related Macular Degeneration (AMD)

Observational
See the trial
voir la fiche